Dr. Thinle Chodon Dr. Thinle Chodon

Thinle Chodon

MD, PhD

Special Interests:

Immunotherapy Vaccines and adoptive cell therapy cGMP cell manufacture

About Me

Biography:

Dr. Thinle Chodon was recruited in September 2013 as an Assistant Member and Associate Director of the Therapeutic Cell Production Facility (TCPF) at the Center For Immunotherapy (CFI). She now serves as the Director of the CFI Translational Research Operations. At the University of California, Los Angeles, she led Dr. Antoni Ribas' lab and cGMP operation for clinical trials. She developed and optimized the standard operating procedures for the manufacture of genetically engineered T cells, peripheral blood stem cells, dendritic cells, and was the key person manufacturing these cells for the patients enrolled in various clinical trials.

Dr. Chodon received her MD and her surgical training from Tribhuvan University Institute of Medicine, Nepal and her PhD from the School of Medicine, Hokkaido University, Japan. Dr. Chodon has authored 33 research articles.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Member, Center for Immunotherapy
  • Facility Director, Center for Immunotherapy Translational Research Operations
  • Director, cGMP Therapeutic Cell Production Facility

Background

Education and Training:

  • 2001 - PhD - School of Medicine, Hokkaido University, Japan
  • 1995 - MD (MBBS) - Tribhuvan University Institute of Medicine, Nepal

Residency:

  • 2001 - Clinical Training - Department of Plastic & Reconstructive Surgery, Graduate School of Medicine, Hokkaido University, Japan
  • 1996 - Department of Surgery - Tribhuvan University Teaching Hospital, Nepal

Board Certification:

  • 1995 - Nepal Medical Council

Professional Memberships:

  • Roswell Park Cancer Center Membership (Tumor Immunology & Immunotherapy (TII) Program)
  • American Association for Cancer Research
  • Japan Society of Plastic & Reconstructive Surgery

Research

Research Overview:

Dr. Chodon’s research interests are in immunotherapy, vaccines and adoptive cell therapy and cGMP cell manufacture. Her expertise includes optimization of standard operating procedures for cGMP manufacture of transgenic T cells, stem cells and dendritic cells to be used in clinical trials, planning and writing clinical trial protocols, IND (investigational new drug) applications and other regulatory documents.

Dr. Chodon’s current research focus is to determine factors that enhance the development of re-engineered peripheral blood derived stem cells into efficient anti-tumor immune cells, with ability to recognize and kill cancer cells and persist for durable clinical responses. The ultimate goal is to develop new and better approaches for genetic engineering of stem cells to be tested within a clinical trial for the treatment of late stage advanced cancers.


Publications

Full Publications list on PubMed

Tumeh P.C., Koya R.C., Chodon T., Graham N.A., Graeber T.G., Comin-Anduix B., Ribas A. The impact of Ex Vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. Journal of Immunotherapy 2010 Oct. 33(8), 759-768 (PMID: 20842061)

Chodon T.*, Comin-Anduix B.*, Sazegar H., Matsunaga D., Mok S., Jalil J., Escuin-Ordinas H., Chmielowski B., Koya RC, Ribas A. The oncogenic BRAF kinase inhibitor PLX 4032/ RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clinical Cancer Research 2010; 16: 6040-6048 (PMID: 21169256) *These authors contributed equally to this work.

Koya R.C., Mok S., Otte N., Blacketor K.J., Comin-Anduix B., Tumeh P.C., Minasyan A., Graham N., Graeber T.G., Chodon T., Ribas A. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Research, 2012 Aug 15; 72(16): 3928-37 (PMCID: PMC3422880)

Birkhäuser F.D., Koya R.C., Neufeld C., Rampersaud E.N., Lu X., Micewicz E.D., Chodon T., Atefi M., Kroeger N., Chandramouli G.V., Li G., Said J.W., McBride W.H., Kabbinavar F.F., Ribas A., Pantuck A.J., Belldegrun A.S., Riss J. Dendritic Cell-Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma: Efficacy, Safety, and Activity of Ad-GM·CAIX in Immunocompetent Mouse Models. J Immunotherapy 2013 Feb; 36(2): 102-11 (PMID: 23377663, PMCID: in process)

Ma C., Fan R., Chodon T., Koya R.C., Wu Z., Ng C., Avramis E., Cochran A.J., Witte O.N., Baltimore D., Chmielowski B., Economou J.S., Anduix B.C., Ribas A., Heath J.R. Multifunctional T Cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. Cancer Discovery 2013 April; 3(4): 418- 429 (PMCID: PMC3716460)

Chodon T., Comin-Anduix B., Chmielowski B., Koya R.C., Wu Z., Auerbach M., Ng C., Avramis E., Seja E., Villanueva A., McCannel T.A., Ishiyama A., Czernin J., Radu C.G., Wang X., Gjertson D.W., Cochran A.J., Cornetta K., Wong D.J.L., Kaplan-lefko P., Hamid O., Samlowski W., Cohen P.A., Daniels G.A., Mukherji B., Yang L., Zack J.A., Kohn D.B., Heath J.R., Glaspy J.A., Witte O.N., Baltimore D., Economou J.S., RibasA. Adoptive transfer of MART-1 T cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clinical Cancer Research 2014 Mar 14 [Epub ahead of print 10.1158/1078-0432.CCR-13-3017]

Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014 Jul 18. pii: canres.0376.2014. [Epub ahead of print] PubMed PMID: 25038231.